The expectorant drugs market is projected to generate USD 17,648.2 million in 2024. expectorant drugs market revenue is predicted to reach USD 38,455.4 million by 2034. A CAGR of 4.3% is expected for the expectorant drugs market during the forecast period.
| Attributes | Key Insights |
|---|---|
| Expectorant Drugs Market Value in 2024 | USD 17,648.2 million |
| Projected Industry Value in 2034 | USD 38,455.4 million |
| Value-based CAGR from 2024 to 2034 | 4.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Pandemics such as COVID-19 have emphasized the need to maintain good respiratory health. Expectorants may become more popular as respiratory health becomes more widely understood. Expectorant drugs could benefit pharmaceutical companies through government initiatives to improve respiratory health.
Individuals may be more willing to spend on respiratory health medications as healthcare expenditures rise worldwide. As a result, expectorant drug sales could increase. Due to the prevalence of respiratory ailments among smokers in certain regions, smoking rates may support the demand for expectorant medicines.
Principal Consultant
Expectorant drugs were worth USD 16,384.6 million in 2023. The market showed a growth rate of 5% from 2019 to 2023. More targeted therapies could lead to more effective expectorants, resulting from advances in medical research. The potential for the use of monoclonal antibodies and gene therapies in the treatment of respiratory conditions and the enhancement of expectorant effectiveness could be explored using biological therapies.
Personalized medicine and genomic advances could lead to an emphasis on tailoring expectorant treatment to individual genetic profiles. As a result, treatment efficacy could be enhanced and side effects could be minimized. Drug delivery systems using nanotechnology may be able to target the respiratory system more precisely and may improve the effectiveness of expectorant medicines.
Medications with improved expectorant properties could be combined or formulated in new forms to minimize adverse effects and maximize efficiency. Inhalers that track respiratory health could be integrated into digital health solutions, such as monitoring devices or smart inhalers, allowing treatment plans to be optimized, including how expectorant drugs are used.
| Attributes | Details |
|---|---|
| HCAGR from 2019 to 2023 | 5% |
| FCAGR from 2024 to 2034 | 4.3% |
Increasing rates of respiratory diseases and chronic conditions are expected to drive demand in future years. Due to their prevalence, mucus clearance and respiratory symptoms continue to be common conditions that lead to a high demand for medications. Respiratory illnesses are more prevalent in the aging population. Increasing environmental conditions and climate change are leading to a rise in respiratory conditions worldwide.
The development or exacerbation of respiratory conditions can be influenced by environmental factors such as pollution and irritation. Environmental factors will continue to affect respiratory health in the future due to urbanization and industrialization.
Research and development in the pharmaceutical industry may contribute to the development of stronger expectorants in the future. A new generation of drug formulations and delivery systems that provide improved therapeutic options could drive market growth.
Expectorant drugs are influenced by government initiatives to improve respiratory health and healthcare access. Increased use of expectorants might result from policies aimed at reducing the burden of respiratory diseases.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Expectorant drugs are expected to face strict laws restricting their use and sale. In January 2018, the FDA announced that cough suppressants with codeine are not to be given to children under 18. A similar ban was imposed in 2017 by Health Canada with regard to the sale of cough suppressants without a prescription. Several severe laws are expected to hamper the expansion of the expectorant drug market.
Several over-the-counter and alternative treatments are competing with expectorant drugs. Pricing strategies and market share can be affected by competitive conditions, reducing market growth. Consumers or healthcare professionals may report adverse reactions and safety concerns, potentially inhibiting the growth of the expectorant drugs market.
A lack of consumer awareness and understanding about expectorant drug benefits may hinder the growth of the market. Alternative approaches to managing respiratory symptoms, such as homeopathic or natural remedies, can appeal to some individuals. Alternatives to expectorants may reduce the demand for them
The following table shows the top five countries by revenue, led by China and India. Research and development activities and the demand for OTC medicines drive the popularity of expectorant drugs in the market. These two countries are predicted to increase their expectorant drug sales through 2034.
Forecast CAGRs of 2024 to 2034
| Attributes | Details |
|---|---|
| The United States | 6.8% |
| Germany | 4.5% |
| India | 7.2% |
| China | 8.1% |
| The United Kingdom | 6.7% |
American consumers are experiencing an increase in demand for expectorant drugs in the market. It is expected that the market will reach USD 4,465.81 million in 2024. A CAGR of 6.8% is projected for the market through 2034. The United States is expected to maintain its dominance in North America, with a market share of 29.3% in 2024. A growing number of research and development activities will likely drive demand in the coming years.
Government policies and approvals are expected to drive the market demand for these drugs in the near future. The approval of new expectorant drugs in this country will boost their growth in the coming years. Aurobindo Pharma Limited, for example, gained FDA approval in 2017, when Food & Drug Administration (FDA) approved extended-release tablets containing Dextromethorphan Hydrobromide and Guaifenesin, aimed at allowing coughs to become more effective by loosening mucus and bronchial secretions. Consequently, expectorant drugs are growing rapidly in the country.
Germany is expected to dominate the expectorant drug market. A CAGR of 4.5% is projected for Germany over the forecast period. Flu-related complications are more common among older adults than they are in young, healthy adults. With the aging process, immune defenses diminish, which is one of the factors that can lead to the increased risk of getting infected.
A large percentage of the German population is over the age of 65. Population Reference Bureau (PRB) data shows that Germany represents 21.4% of the elderly population. Because of the large population of elderly people, expectorant drugs are more likely to be used, as they are at higher risk for developing flu.
India is expected to lead the expectorant drugs market in the coming years. The market is expected to record a CAGR of 7.2% during the forecast period. A high incidence of cough is expected to push India's expectorant drug market to grow over the forecast period. The growing population and increasing disposable income will likely drive the market demand for these drugs.
An analysis of statistics published in 2016 in the Journal of the Association of Physicians of India found that around 54% of the Indian population had a cough. The Journal of the Association of Physicians of India reports that 54% of India's population suffers from cough.
Expectorant drugs are gaining popularity in China. The market is anticipated to reach an 8.1% CAGR by 2034. China's healthcare system is heavily reliant on traditional Chinese medicine. The system incorporates a variety of herbal remedies and treatments, including expectorant herbs to treat respiratory diseases. TCM's popularity and acceptance in China may influence the demand for expectorant drugs in the future.
Expectorants are in high demand worldwide, and this trend is also evident in China. Increasing consumer interest in oral medications, including expectorants, may contribute to their demand. China is also plagued by respiratory diseases, as are many other countries. Colds, pneumonia, bronchitis, and other conditions requiring symptomatic relief and expectorant medications may influence the demand for expectorants.
The United Kingdom is expected to drive demand for expectorant drugs in the coming years. By 2034, the market is expected to expand at a CAGR of 6.7%. As cold and flu season approaches, expectorant drug demand in the United Kingdom could fluctuate. As respiratory infections increase, medications to treat cough and congestion will be more in demand.
Since the cost of living has increased in the United Kingdom, individuals may seek over-the-counter expectorant drugs at the pharmacy to treat their symptoms. Medications like these can relieve nasal congestion and cough symptoms temporarily without a prescription. Consumer preferences, medical practices, and population demographics all play a role in influencing the overall demand for expectorant drugs in the United Kingdom.
According to market forecasts, the over-the-counter segment will dominate with a 75% share over the forecast period. The secretion enhancers drug type is projected to hold a market share of 59.7%.
| Attributes | Details |
|---|---|
| Secretion Enhancers Market Share in 2024 | 59.7% |
| Over-the-counter Market Share in 2024 | 75% |
The market for secretion enhancers is expected to grow rapidly during the forecast period. By 2024, secretion enhancers will hold a 59.7% of the global market share. As part of the body's defense system against viruses and pollutants, bronchial secretion mechanisms play an important role.
Secretion enhancers are useful for treating a wide variety of respiratory disorders. New drugs or formulations that are specifically formulated to enhance secretion may be discovered and developed through ongoing research and development in respiratory medicine.
A growing number of innovative products for children will increase demand for OTC products. Over-the-counter (OTC) is expected to hold a 75.0% global market share by 2024. Due to consumers' self-medication for colds and coughs, OTC expectorants are becoming more popular. A CAGR of 8.6% is expected to rise in the next few years.
The availability of OTC expectorant drugs offers consumers convenience by removing the need for a prescription. As individuals can easily obtain OTC expectorant drugs for self-treatment, they may contribute to the demand for OTC expectorants. The cost of over-the-counter expectorants is usually lower than that of prescription medications. Affordability may be an important factor for individuals who are looking for cost-effective respiratory treatment options
With a variety of international and local manufacturers, the market is fragmented. These companies use mergers, acquisitions, and the growth of their product ranges as marketing methods to gain market share.
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | USD 17,648.2 million |
| Projected Market Valuation in 2034 | USD 38,455.4 million |
| Value-based CAGR 2024 to 2034 | 4.3% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in USD million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; The Middle East & Africa |
| Key Market Segments Covered | Drug Type, Dosage Form, Product Type, Distribution Channel, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Argentina, Germany, The United Kingdom, France, Spain, Italy, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC Countries, Turkiye, South Africa, North Africa |
| Key Companies Profiled | Abbott Laboratories; Acella Pharmaceuticals LLC; Astrazeneca Plc.; Cipla Limited; Dabur India Ltd; Glenmark Pharmaceuticals Limited; Johnson and Johnson; Merck KGaA; Novartis International AG; Pfizer Inc.; Proctor and Gamble Co; Reckitt Benckiser Group plc; Sanofi SA; The Himalaya Drug Company; Perrigo Company plc; Vernalis plc; Tris Pharma Inc.; Aytu BioScience Inc.; Mayne Pharma Inc.; Taro Pharmaceutical Industries Ltd.; Amneal Pharmaceuticals LLC; Aurobindo Pharma Ltd; GlaxoSmithKline plc. |
The expectorant drugs market is expected to be valued at USD 17,648.2 million in 2024.
Sales of expectorant drugs are projected to rise at a 4.3% CAGR from 2024 to 2034.
The expectorant drugs industry is predicted to reach USD 38,455.4 million by 2034.
Consumption of secretion enhancers is expected to be high, accumulating a 59.7% revenue share in 2024.
The over-the-counter (OTC) segment is predicted to account for 75% of the market.
1. Executive Summary 2. Market Overview 3. Market Trends & Dynamics 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Value or Indication in USD Million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug 7.1. Secretion Enhancer 7.1.1. Potassium Citrate 7.1.2. Potassium Iodide 7.1.3. Sodium Citrate 7.1.4. Guaiphenesin 7.1.5. Ammonium Chloride 7.1.6. Others 7.2. Mucolytics 7.2.1. Bromhexine 7.2.2. Ambroxol 7.2.3. Acetyl Cysteine 7.2.4. Carbocisteine 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form 8.1. Oral Solid 8.1.1. Powder & Granules 8.1.2. Tablet 8.1.3. Capsule 8.1.4. Lozenge 8.2. Oral Liquid 8.2.1. Syrup 8.2.2. Solution 8.2.3. Suspension 8.2.4. Elixir 8.3. Inhalant 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 9.1. Over-The-Counter (OTC) 9.2. Prescription Drug 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 10.1. Hospital Pharmacies 10.2. Retail Store 10.3. Drug Store 10.4. Online Pharmacies 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa (MEA) 12. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16. South Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17. Oceania Market 2019 to 2023 and Forecast 2024 to 2034 18. Middle East and Africa (MEA) Market Analysis 2019 to 2023 and Forecast 2024 to 2034 19. Market Structure Analysis 20. Competition Analysis 20.1. Abbott Laboratories 20.2. Acella Pharmaceuticals LLC 20.3. Astrazeneca plc 20.4. Cipla Limited 20.5. Dabur India Ltd 20.6. Glenmark Pharmaceuticals Limited 20.7. Johnson and Johnson 20.8. Merck KGaA 20.9. Novartis International AG 20.10. Pfizer Inc 20.11. Proctor and Gamble Co 20.12. Reckitt Benckiser Group plc 20.13. Sanofi SA 20.14. The Himalaya Drug Company 20.15. Perrigo Company plc 20.16. Vernalis plc 20.17. Tris Pharma Inc. 20.18. Aytu BioScience, Inc. 20.19. Mayne Pharma Inc. 20.20. Taro Pharmaceutical Industries Ltd. 20.21. AMillioneal Pharmaceuticals LLC 20.22. Aurobindo Pharma Ltd 20.23. GlaxoSmithKline plc. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Expectorant Drugs Market
